DEPDC1 as a metabolic target regulates glycolysis in renal cell carcinoma through AKT/mTOR/HIF1α pathway

Abstract Renal cell carcinoma (RCC) is considered a “metabolic disease” characterized by elevated glycolysis in patients with advanced RCC. Tyrosine kinase inhibitor (TKI) therapy is currently an important treatment option for advanced RCC, but drug resistance may develop in some patients. Combining...

Descrición completa

Detalles Bibliográficos

Principais autores:	Si-chen Di, Wen-jin Chen, Wei Yang, Xiang-min Zhang, Ke-qin Dong, Yi-jun Tian, Ye Sun, Cheng Qian, Jia-xin Chen, Zi-chang Liu, Zi-xuan Gong, Jian Chu, Wang Zhou, Xiu-wu Pan, Xin-gang Cui
Formato:	Artigo
Idioma:	Inglês
Publicado:	Nature Publishing Group 2024-07-01
Series:	Cell Death and Disease
Acceso en liña:	https://doi.org/10.1038/s41419-024-06913-1
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!